Parkinson's Disease Trial, Recruiting (NCT06487364)

Parkinson's Disease Trial, Recruiting NCT06487364 Sponsor: Emre Şenocak Condition: Parkinson's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06487364 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Parkinsons Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are regularly seeing a neurologist and currently taking medication for their condition
People whose Parkinson's disease severity falls within stages 1 to 3 on the Hoehn and Yahr Scale, which generally means mild to moderate symptoms
People who score above 24 points on a standard memory and thinking assessment, indicating no significant cognitive impairment

Who may not be able to join:

People who have a secondary neurological condition (a separate neurological disease in addition to their primary diagnosis)
People who have had surgery or an injury affecting their arm, hand, or shoulder
People who were experiencing pain before the treatment program began
People whose medication was changed at any point during the study
People who have symptoms of anxiety or depression
People who use alcohol or recreational drugs
People who have uncorrectable vision problems (not fixable with glasses) or hearing loss

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Murat Emirzeoğlu, PhD, Karadeniz Technical University

Phone: +90 553 569 56 92

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06487364

Sponsor: Emre Şenocak

Phase: Not Applicable

Status: Recruiting

Condition: Parkinson's Disease

Trial contact: +90 553 569 56 92

More information: https://clinicaltrials.gov/study/NCT06487364

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are regularly seeing a neurologist and currently taking medication for their condition
People whose Parkinson's disease severity falls within stages 1 to 3 on the Hoehn and Yahr Scale, which generally means mild to moderate symptoms
People who score above 24 points on a standard memory and thinking assessment, indicating no significant cognitive impairment

Who may not be able to join:

People who have a secondary neurological condition (a separate neurological disease in addition to their primary diagnosis)
People who have had surgery or an injury affecting their arm, hand, or shoulder
People who were experiencing pain before the treatment program began
People whose medication was changed at any point during the study
People who have symptoms of anxiety or depression
People who use alcohol or recreational drugs
People who have uncorrectable vision problems (not fixable with glasses) or hearing loss

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Emre Şenocak

Registry

ClinicalTrials.gov

Start date

13 May 2024

Est. completion

17 January 2025

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Parkinson Disease Questionnaire-8; Parkinson Disease Questionnaire-8; Parkinson Disease Questionnaire-8

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov